Abbvie IncChange company Symbol lookupSelect an option...ABBV Abbvie IncKGJI Kingold Jewelry IncPARA Paramount GlobalTFINP Triumph Financial IncHWKN Hawkins IncCOUP Coupa Software IncACAZF Acadian Timber CorpBSX Boston Scientific CorpACDVF Air CanadaDCFCW Tritium DCFC Equity Warrant Exp 13th Jan 2027 *W EXP 01/13/2027Go
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
KGJI Kingold Jewelry Inc
PARA Paramount Global
TFINP Triumph Financial Inc
HWKN Hawkins Inc
COUP Coupa Software Inc
ACAZF Acadian Timber Corp
BSX Boston Scientific Corp
ACDVF Air Canada
DCFCW Tritium DCFC Equity Warrant Exp 13th Jan 2027 *W EXP 01/13/2027
Health Care : Biotechnology | Large Cap Value
Company profileAbbVie Inc. is a research-based biopharmaceutical company, which is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta; aesthetics products that include Botox Cosmetic, Juvederm Collection and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products consists of Lumigan, Alphagan and Restasis; women's health products include Lo Loestrin, Orilissa and others; and other products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. Its products are sold to wholesalers, government agencies, health care facilities and independent retailers. It also discovers and develop antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).
Premarket |
|
|
| ||
Market Hours |
|
|
|
|
|
Latest Earnings (Q3 ending 09/2022)
- Q3 Non-GAAP earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
- $3.66
- Q3 Consensus estimate
- $3.57
Latest Earnings Estimate Range
- Highest
estimate - $3.70
- Mean
estimate - $3.57
- Lowest
estimate - $3.51
Quarterly Consensus Estimates and Ranges
ABBV's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.